iMAb supplies human monoclonal antibody leads to biotechnology and pharmaceutical companies, with a view to their development and marketing for therapeutic or diagnostic applications. To that end, iMAb's mission is to generate antibody hits developed to match customer specifications and, at lead validation, to transfer the lead antibody sequence along with full ownership and exclusive rights for the customer to carry on its drug development.
| Website | http://www.imab-labs.com |
| Revenue | $1 million |
| Employees | 18 (18 on RocketReach) |
| Founded | 2017 |
| Technologies | |
| Industry | Biotechnology, Charitable Organizations & Foundations, Organizations |
| Keywords | Monoclonal Antibodies, Therapeutic Antibodies, Antibody Discovery, Biotechnology, Pharmaceutical, Drug Development, Antibody Engineering, Diagnostic Antibodies, Immunology Research, Biopharmaceutical, Human Antibodies, Preclinical Development, Lead Optimization, Therapeutic Proteins, Clinical Development, Biologics, Research Antibodies, Pharmaceutical Research, Biotech Research |
| Competitors | Johnson & Johnson, Roche, Merck AH, AbbVie, Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Lilly India +41 more (view full list) |
| SIC | SIC Code 673 Companies, SIC Code 672 Companies, SIC Code 67 Companies |
| NAICS | NAICS Code 5259 Companies, NAICS Code 81 Companies, NAICS Code 52591 Companies, NAICS Code 525 Companies, NAICS Code 52 Companies, NAICS Code 813 Companies |
Looking for a particular iMAb employee's phone or email?
The iMAb annual revenue was $1 million in 2026.
Sylvain Yon is the CEO of iMAb.
18 people are employed at iMAb.
The NAICS codes for iMAb are [5259, 81, 52591, 525, 52, 813].
The SIC codes for iMAb are [673, 672, 67].